Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,473JPY
28 Apr 2017
Change (% chg)

¥19 (+0.77%)
Prev Close
¥2,454
Open
¥2,470
Day's High
¥2,478
Day's Low
¥2,462
Volume
1,587,800
Avg. Vol
1,806,058
52-wk High
¥2,750
52-wk Low
¥2,192

4568.T

Chart for 4568.T

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)

Overall

Beta: 0.85
Market Cap(Mil.): ¥1,753,385.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 2.63

Financials

  4568.T Industry Sector
P/E (TTM): 27.76 29.18 30.12
EPS (TTM): 89.08 -- --
ROI: 3.57 13.76 13.28
ROE: 4.74 14.71 14.44

BRIEF-Daiichi Sankyo makes 15 bln yen investment

* Daiichi Sankyo - making initial 15 billion yen investment to optimize and enhance manufacturing capabilities to support growing antibody drug conjugate pipeline Source text for Eikon: Further company coverage:

Apr 27 2017

BRIEF-HTG Molecular says entered into master services agreement with Daiichi Sankyo Company

* Htg molecular diagnostics - entered into master services agreement with daiichi sankyo company, ltd for work to be performed in htg's veri/o laboratory

Apr 17 2017

BRIEF-Daiichi Sankyo announces new analyses

* Daiichi Sankyo Inc announces new analyses of once-daily savaysa (edoxaban) in patients with non-valvular atrial fibrillation to be presented at the acc 66th annual scientific session

Mar 13 2017

BRIEF-Sosei Group unit signs alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED.

* Says its subsidiary Heptares signed an alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED. on March 13

Mar 13 2017

BRIEF-EMA recommends approval of Daiichi Sankyo's anticoagulant

* EU Medicines Agency recommends approval Of Daiichi Sankyo's anticoagulant Edoxaban

Feb 24 2017

BRIEF-Daiichi Sankyo and ArQule's carcinoma drug failed in late-stage trial

* Daiichi Sankyo and Arqule announce the completion of the metiv-hcc phase 3 study of tivantinib in second-line treatment of met-overexpressing hepatocellular carcinoma

Feb 17 2017

BRIEF-Daiichi Sankyo to close Japan research unit Asubio Pharma

* Says move aimed at further reorganising its research and development structure Source text for Eikon: Further company coverage: (Reporting By Chris Gallagher)

Feb 10 2017

BRIEF-Daiichi Sankyo initiates phase 1/2 study of novel antibody drug conjugate in patients unresectable breast cancer

* Daiichi sankyo initiates phase 1/2 study of novel antibody drug conjugate u3-1402 in patients with her3-positive metastatic or unresectable breast cancer Source text for Eikon: Further company coverage:

Jan 18 2017

BRIEF-Kite Pharma establishes strategic partnership with Daiichi Sankyo

* Kite Pharma establishes strategic partnership with Daiichi Sankyo to develop and commercialize axicabtagene ciloleucel (kte-c19) in Japan

Jan 09 2017

Kite Pharma partners with Japan's Daiichi for cancer therapy

Kite Pharma Inc said on Monday it partnered with Daiichi Sankyo Co Ltd to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $250 million in payments.

Jan 09 2017

More From Around the Web

Earnings vs. Estimates